Soumyajit Das1, Satvinder Singh Bakshi2, Ramesh Seepana2. 1. Department of ENT, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, 522503, India. drsoumya_entamch@rediffmail.com. 2. Department of ENT, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, 522503, India.
Abstract
INTRODUCTION: Autoimmune inner disease (AIED) is an uncommon cause of sensorineural hearing loss and poses a diagnostic challenge. The present study aims to review the existing knowledge on the clinicopathological aspects, the diagnostic challenges, and therapeutic interventions in AIED. DISCUSSION: The incidence of AIED is less than five cases per 100,000 population. There are no definite seromarkers which make diagnosis of AIED difficult. Even though various markers have been studied, their sensitivity and specificity have not been replicated in the clinical scenario. The treatment of the condition is also an enigma. Corticosteroids are the drug of choice and require long-term use to prevent relapse. Various other therapeutic agents have been studied in a small cohort of patients, but the efficacy of these drugs needs to be validated in a large multicentric trial. CONCLUSION: Timely intervention can restore hearing loss in AIED patients, but the clinician has to find a delicate balance between the hearing outcome and the potential side effects resulting from long-term use of the drugs. Treatment of steroid resistant AIED is a challenge and there are no universal guidelines for the same. AIED being an uncommon diagnosis, multicentric trials and collaboration are required to formulate diagnostic criteria and therapeutic guidelines.
INTRODUCTION:Autoimmune inner disease (AIED) is an uncommon cause of sensorineural hearing loss and poses a diagnostic challenge. The present study aims to review the existing knowledge on the clinicopathological aspects, the diagnostic challenges, and therapeutic interventions in AIED. DISCUSSION: The incidence of AIED is less than five cases per 100,000 population. There are no definite seromarkers which make diagnosis of AIED difficult. Even though various markers have been studied, their sensitivity and specificity have not been replicated in the clinical scenario. The treatment of the condition is also an enigma. Corticosteroids are the drug of choice and require long-term use to prevent relapse. Various other therapeutic agents have been studied in a small cohort of patients, but the efficacy of these drugs needs to be validated in a large multicentric trial. CONCLUSION: Timely intervention can restore hearing loss in AIEDpatients, but the clinician has to find a delicate balance between the hearing outcome and the potential side effects resulting from long-term use of the drugs. Treatment of steroid resistant AIED is a challenge and there are no universal guidelines for the same. AIED being an uncommon diagnosis, multicentric trials and collaboration are required to formulate diagnostic criteria and therapeutic guidelines.
Authors: Moo-Jin Baek; Hyun-Min Park; Justin M Johnson; Cengiz Z Altuntas; Daniel Jane-Wit; Ritika Jaini; C Arturo Solares; Dawn M Thomas; Edward J Ball; Nahid G Robertson; Cynthia C Morton; Gordon B Hughes; Vincent K Tuohy Journal: J Immunol Date: 2006-09-15 Impact factor: 5.422
Authors: Massimo Ralli; Vittorio D'Aguanno; Arianna Di Stadio; Armando De Virgilio; Adelchi Croce; Lucia Longo; Antonio Greco; Marco de Vincentiis Journal: J Immunol Res Date: 2018-08-19 Impact factor: 4.818
Authors: Nadia L Samaha; Mohamad M Almasri; J Dixon Johns; Michael Hoa Journal: Curr Opin Otolaryngol Head Neck Surg Date: 2021-10-01 Impact factor: 1.814